Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | BI 754111 |
Synonyms | |
Therapy Description |
BI 754111 is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 754111 | BI754111|BI-754111|Miptenalimab | Immune Checkpoint Inhibitor 141 LAG3 Antibody 17 | BI 754111 (miptenalimab) is a monoclonal antibody that targets LAG3 and inhibits binding of MHC II molecules to increase cytokine production by T-cells and prevent tumor growth (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4547). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03156114 | Phase I | BI 754091 BI 754111 | This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. | Active, not recruiting | USA | ESP | CAN | 2 |
NCT03697304 | Phase II | BI 754091 BI 754111 | Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. | Active, not recruiting | USA | CAN | 1 |